Nerve Sheath Neoplasms: Clinical Trials

27 trials for Nerve Sheath Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 7 terminated, 3 active not recruiting, 3 unknown. 27 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 327Completed 12, Terminated 7, Active not recruiting 3, Unknown 3, Recruiting 2
Phase 26Terminated 4, Completed 1, Unknown 1

Follow Nerve Sheath Neoplasms: new trials by email Literature Review of Nerve Sheath Neoplasms trials Research Report on Nerve Sheath Neoplasms

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
TQ-B3234 capsules, TQ-B3234 placebo - Plexiform Neurofibroma
Phase 3RecruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.1772026-03-312026-05-27
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
Steroids therapy, Placebo - Vestibular Schwannoma, Facial Nerve Paralysis
Phase 3RecruitingBeijing Tiantan Hospital3642025-10-092026-10-26
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily; - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 3Active not recruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.1672023-06-202025-03-06
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
REC-2282, Placebo - Neurofibromatosis Type 2
Phase 2 / Phase 3TerminatedRecursion Pharmaceuticals Inc.252022-06-202026-08-17
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Selumetinib, Placebo - Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Phase 3Active not recruitingAstraZeneca1452021-11-192026-11-12
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
NPC-12G gel - Neurofibromatosis
Phase 3TerminatedNobelpharma1002020-07-082022-05-24
Vitamin D3 in Sensory Recovery After Digital NERVe Suture (D3NERV).
Cholecalciferol, Placebos - Digital Nerve Injury
Phase 3UnknownUniversity Hospital, Caen722020-01-202021-08-31
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment - Low Grade Glioma, Neurofibromatosis Type 1
Phase 3Active not recruitingNational Cancer Institute (NCI)1652020-01-152026-11-12
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Brolucizumab, Aflibercept - Age-Related Macular Degeneration
Phase 3TerminatedNovartis Pharmaceuticals5352018-10-302023-01-30
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Acceptance and Commitment Therapy (ACT) - Neurofibromatosis Type 1, Plexiform Neurofibromas
Phase 3CompletedNational Cancer Institute (NCI)662015-07-072022-06-14
Effect of Lamotrigine on Cognition in NF1
Lamotrigine, Placebo - Neurofibromatosis Type 1
Phase 2 / Phase 3TerminatedErasmus Medical Center412014-10-012020-04-14
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)1402014-08-122026-06-17
Stereotactic Radiation in Vestibular Schwannoma
stereotactic radiotherapy, stereotactic radiosurgery - Vestibular Schwannoma
Phase 3UnknownRamathibodi Hospital2002011-10-012011-10-10
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis - Sarcoma
Phase 2 / Phase 3TerminatedEuropean Organisation for Research and Treatment of Cancer - EORTC1332011-05-012014-08-08
Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain
Ralfinamide - Pain
Phase 3CompletedNewron Pharmaceuticals SPA4112009-03-202017-09-15
Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery
methylprednisolone - Facial Palsy
Phase 3CompletedAssistance Publique - Hôpitaux de Paris3132007-03-012012-07-10
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery - Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Phase 3CompletedChildren's Oncology Group5882007-02-052022-04-28
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
imatinib mesylate - Malignant Peripheral Nerve Sheath Tumors
Phase 2 / Phase 3TerminatedNovartis Pharmaceuticals112006-05-012012-08-07
First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas
Erbium-YAG laser vaporization - Cutaneous Neurofibromas
Phase 2 / Phase 3UnknownMedical University of Vienna122006-04-012011-07-13
Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma
radiotherapy - Sarcoma
Phase 3CompletedSheffield Teaching Hospitals NHS Foundation Trust2162006-03-012021-03-18

Showing 20 of 27. Sign in to see all of them.

Narrower conditions

Neurofibrosarcoma (11)  ·  Fibrosarcoma (10)  ·  Histiocytoma, Malignant Fibrous (10)  ·  Leiomyosarcoma (10)  ·  Sarcoma (10)  ·  Sarcoma, Synovial (10)  ·  Hemangiosarcoma (9)  ·  Liposarcoma (9)  ·  Hemangiopericytoma, Malignant (6)  ·  Neurofibromatosis 1 (6)  ·  Sarcoma, Alveolar Soft Part (6)  ·  Malignant mesenchymal tumor (5)  ·  Chondrosarcoma, Extraskeletal Myxoid (4)  ·  Neurofibroma, Plexiform (4)  ·  Rhabdomyosarcoma (4)

Broader conditions

Neoplasms (27)  ·  Neoplasms by Histologic Type (27)  ·  Neoplasms, Nerve Tissue (27)  ·  Nervous System Diseases (25)  ·  Neurofibroma (21)  ·  Neuromuscular Diseases (19)  ·  Peripheral Nervous System Diseases (19)  ·  Nervous System Neoplasms (18)  ·  Peripheral Nervous System Neoplasms (18)  ·  Neoplasms, Connective Tissue (11)  ·  Neoplasms, Connective and Soft Tissue (11)  ·  Neoplasms, Fibrous Tissue (11)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10)  ·  Genetic Diseases, Inborn (10)

Interventions

Doxorubicin (8)  ·  Ifosfamide (7)  ·  Radiotherapy (5)  ·  Filgrastim (2)  ·  AZD 6244 (1)  ·  Acceptance and Commitment Therapy (1)  ·  Carboplatin (1)  ·  Chemotherapy, Adjuvant (1)  ·  Cholecalciferol (1)  ·  Combined Modality Therapy (1)  ·  Control Groups (1)  ·  Diathermy (1)  ·  Etoposide (1)  ·  HDAC-42 (1)  ·  Imatinib Mesylate (1)

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC (6)  ·  National Cancer Institute (NCI) (3)  ·  Novartis Pharmaceuticals (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  AstraZeneca (1)  ·  Beijing Tiantan Hospital (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  Children's Oncology Group (1)  ·  Endo USA Inc., a Keenova Therapeutics Company (1)  ·  Erasmus Medical Center (1)  ·  Medical University of Vienna (1)  ·  Newron Pharmaceuticals SPA (1)  ·  Nobelpharma (1)  ·  Ramathibodi Hospital (1)

Countries

United States (10)  ·  United Kingdom (8)  ·  Canada (7)  ·  France (7)  ·  Germany (7)  ·  Spain (6)  ·  Belgium (5)  ·  Netherlands (5)  ·  Austria (4)  ·  China (4)  ·  Denmark (4)  ·  Puerto Rico (4)  ·  Slovakia (4)  ·  Poland (3)  ·  Switzerland (3)

Top investigators

A.N. Van Geel, MD (1)  ·  Aaron R Weiss (1)  ·  Alice P. Chen, MD (1)  ·  Henriette A Moll, MD, PhD (1)  ·  Ian R. Judson, MA, MD, FRCP (1)  ·  James E. Butrynski, MD (1)  ·  Jason R Fangusaro (1)  ·  Laurence H. Baker, DO, FACOI (1)  ·  Martin Robinson, MD (1)  ·  Nguyen Binh Bui, MD (1)  ·  Paul C. Lorigan, MD (1)  ·  Penella J. Woll, MD, PhD (1)

Results publications

PMID 17634494, PMID 20434400, PMID 22954508, PMID 24618336, PMID 24747207, PMID 28391003, PMID 29450452, PMID 30954717, PMID 31786124, PMID 32702309, PMID 32827353, PMID 33395032, PMID 33548339, PMID 34515544, PMID 34623899, PMID 34666214, PMID 36566574, PMID 37523624, PMID 38757485, PMID 39122389, PMID 39340758, PMID 40121838, PMID 40473450, PMID 41386267, PMID 42035475

NIH funding

U10CA098543 (2), U10CA180886 (2), 2009 (1), 2018 (1), U10CA180830 (1)